Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MRNS Stock Summary
Top 10 Correlated ETFs
MRNS
In the News
MRNS Financial details
Company Rating
Neutral
Market Cap
410.91M
Income
-141.25M
Revenue
30.99M
Book val./share
0.3
Cash/share
2.65
Dividend
-
Dividend %
-
Employees
165
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-4.43
Forward P/E
-
PEG
-0.11
P/S
19.37
P/B
10.87
P/C
0.54
P/FCF
-5.3
Quick Ratio
5.91
Current Ratio
6.38
Debt / Equity
6.54
LT Debt / Equity
5.68
-
-
EPS (TTM)
-2.63
EPS next Y
-
EPS next Q
-
EPS this Y
415.69%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-2.02%
EPS Q/Q
21.31%
-
-
-
-
SMA20
-36.56%
SMA50
-42.28%
SMA100
-6.34%
Inst Own
72.6%
Inst Trans
0.84%
ROA
-67%
ROE
-171%
ROC
-0.74%
Gross Margin
96%
Oper. Margin
-405%
Profit Margin
-432%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.57-11.26
52W High
-86.91%
52W Low
-71.2%
RSI
13.62
Rel Volume
20.85
Avg Volume
440.93K
Volume
9.19M
Perf Week
-82.44%
Perf Month
-84.42%
Perf Quarter
-78.57%
Perf Half Y
-78.82%
-
-
-
-
Beta
0.888
-
-
Volatility
3.31%, 2.27%
Prev Close
20%
Price
1.44
Change
9.09%
MRNS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.06 | 0.42 | 0.65 | 0.58 | |
Net income per share | -3.95 | -2.44 | -2.77 | -0.51 | -2.63 | |
Operating cash flow per share | -3.57 | -2.23 | -1.51 | -2.89 | -2.2 | |
Free cash flow per share | -3.6 | -2.23 | -1.59 | -2.93 | -2.2 | |
Cash per share | 6.73 | 5.13 | 3.35 | 6.16 | 2.8 | |
Book value per share | 6.44 | 5.03 | 1.46 | 2.97 | 0.31 | |
Tangible book value per share | 6.44 | 5.03 | 1.46 | 2.97 | 0.31 | |
Share holders equity per share | 6.44 | 5.03 | 1.46 | 2.97 | 0.31 | |
Interest debt per share | 0.03 | 0.11 | 1.2 | 2.13 | 2.36 | |
Market cap | 117.75M | 332.69M | 435.96M | 155.51M | 584.22M | |
Enterprise value | 27.25M | 194.7M | 353.84M | -12.37M | 574.01M | |
P/E ratio | -2.19 | -4.99 | -4.29 | -7.85 | -4.13 | |
Price to sales ratio | 0 | 193.65 | 28.41 | 6.1 | 18.85 | |
POCF ratio | -2.42 | -5.46 | -7.86 | -1.38 | -4.95 | |
PFCF ratio | -2.4 | -5.46 | -7.47 | -1.36 | -4.95 | |
P/B Ratio | 1.34 | 2.42 | 8.15 | 1.34 | 34.85 | |
PTB ratio | 1.34 | 2.42 | 8.15 | 1.34 | 34.85 | |
EV to sales | 0 | 113.33 | 23.06 | -0.49 | 18.52 | |
Enterprise value over EBITDA | -0.5 | -2.87 | -3.68 | 2.15 | -4.38 | |
EV to operating cash flow | -0.56 | -3.2 | -6.38 | 0.11 | -4.86 | |
EV to free cash flow | -0.56 | -3.2 | -6.06 | 0.11 | -4.86 | |
Earnings yield | -0.46 | -0.2 | -0.23 | -0.13 | -0.24 | |
Free cash flow yield | -0.42 | -0.18 | -0.13 | -0.74 | -0.2 | |
Debt to equity | 0.01 | 0.02 | 0.77 | 0.63 | 6.54 | |
Debt to assets | 0 | 0.02 | 0.3 | 0.28 | 0.64 | |
Net debt to EBITDA | 1.67 | 2.03 | 0.85 | 29.17 | 0.08 | |
Current ratio | 11.72 | 13.06 | 3.03 | 4.38 | 4.07 | |
Interest coverage | 0 | 0 | -37.54 | -10.57 | -7.78 | |
Income quality | 0.9 | 0.9 | 0.56 | 5.7 | 0.83 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 10.8 | 2.43 | 0 | 0 | |
Research and developement to revenue | 0 | 29.75 | 4.79 | 3.14 | 3.19 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0.05 | 0.02 | 0 | |
Capex to revenue | 0 | 0 | -0.19 | -0.07 | 0 | |
Capex to depreciation | -1.4 | 0 | -8.14 | -4.24 | -0.22 | |
Stock based compensation to revenue | 0 | 4.45 | 0.9 | 0.58 | 0.5 | |
Graham number | 23.91 | 16.63 | 9.53 | 5.82 | 4.3 | |
ROIC | -0.61 | -0.48 | -1.02 | -0.71 | -1.02 | |
Return on tangible assets | -0.54 | -0.44 | -0.74 | -0.08 | -0.83 | |
Graham Net | 5.91 | 4.58 | 1.02 | 2.61 | 0 | |
Working capital | 86.1M | 129.43M | 82.36M | 185.68M | 124.62M | |
Tangible asset value | 87.77M | 137.2M | 53.49M | 116M | 16.77M | |
Net current asset value | 83.06M | 126.89M | 39.57M | 97.03M | 11.1M | |
Invested capital | 0.01 | 0.02 | 0.77 | 0.63 | 6.54 | |
Average receivables | 0 | 823K | 2.42M | 4.77M | 5.07M | |
Average payables | 2.62M | 2.49M | 2.67M | 4.73M | 5.17M | |
Average inventory | 0 | -3.14M | -7.8M | -4.62M | 1.25M | |
Days sales outstanding | 0 | 349.7 | 75.78 | 90.94 | 44.75 | |
Days payables outstanding | 2K | 15.98 | 771.98 | 6.81K | 587.97 | |
Days of inventory on hand | 0 | -45.41 | -2.3K | 82.66 | 354.42 | |
Receivables turnover | 0 | 1.04 | 4.82 | 4.01 | 8.16 | |
Payables turnover | 0.18 | 22.84 | 0.47 | 0.05 | 0.62 | |
Inventory turnover | 0 | -8.04 | -0.16 | 4.42 | 1.03 | |
ROE | -0.61 | -0.49 | -1.9 | -0.17 | -8.43 | |
Capex per share | -0.03 | 0 | -0.08 | -0.05 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.16 | 0.2 | 0.12 | 0.14 | 0.13 | |
Net income per share | -0.76 | -0.67 | -0.61 | -0.61 | -0.74 | |
Operating cash flow per share | -0.49 | -0.8 | -0.46 | -0.47 | -0.48 | |
Free cash flow per share | -0.49 | -0.8 | -0.46 | -0.47 | -0.48 | |
Cash per share | 5.35 | 3.85 | 3.34 | 3.27 | 2.65 | |
Book value per share | 2.58 | 1.64 | 1.09 | 1.01 | 0.3 | |
Tangible book value per share | 2.58 | 1.64 | 1.09 | 1.01 | 0.3 | |
Share holders equity per share | 2.58 | 1.64 | 1.09 | 1.01 | 0.3 | |
Interest debt per share | 1.7 | 2.1 | 2.09 | 1.3 | 2.01 | |
Market cap | 178.99M | 357.21M | 570.71M | 434.06M | 616.2M | |
Enterprise value | 11.12M | 312.7M | 548.7M | 367.78M | 605.99M | |
P/E ratio | -1.3 | -2.58 | -4.47 | -3.29 | -3.69 | |
Price to sales ratio | 24.99 | 34.41 | 93.85 | 59.15 | 85.7 | |
POCF ratio | -8.17 | -8.61 | -23.43 | -17.24 | -22.83 | |
PFCF ratio | -8.13 | -8.61 | -23.43 | -17.18 | -22.8 | |
P/B Ratio | 1.54 | 4.2 | 9.95 | 7.96 | 36.76 | |
PTB ratio | 1.54 | 4.2 | 9.95 | 7.96 | 36.76 | |
EV to sales | 1.55 | 30.13 | 90.23 | 50.12 | 84.28 | |
Enterprise value over EBITDA | -0.38 | -10.22 | -18.83 | -11.62 | -17.16 | |
EV to operating cash flow | -0.51 | -7.54 | -22.53 | -14.61 | -22.45 | |
EV to free cash flow | -0.51 | -7.54 | -22.53 | -14.56 | -22.42 | |
Earnings yield | -0.19 | -0.1 | -0.06 | -0.08 | -0.07 | |
Free cash flow yield | -0.12 | -0.12 | -0.04 | -0.06 | -0.04 | |
Debt to equity | 0.63 | 1.23 | 1.84 | 1.36 | 6.54 | |
Debt to assets | 0.28 | 0.46 | 0.53 | 0.37 | 0.64 | |
Net debt to EBITDA | 5.79 | 1.46 | 0.76 | 2.09 | 0.29 | |
Current ratio | 4.38 | 9.26 | 7.6 | 6.38 | 4.07 | |
Interest coverage | -7.92 | -7.95 | -7.47 | 7.46 | -8.24 | |
Income quality | 0.64 | 1.19 | 0.76 | 0.76 | 0.65 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 6.05 | 0 | 2.59 | 0 | 0 | |
Research and developement to revenue | 2.99 | 2.69 | 3.52 | 3.22 | 3.65 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.01 | 0 | 0 | -0.01 | 0 | |
Capex to depreciation | -1.12 | 0 | 0 | -0.6 | -0.27 | |
Stock based compensation to revenue | 0.53 | 0.36 | 0.64 | 0.55 | 0.55 | |
Graham number | 6.65 | 4.97 | 3.86 | 3.73 | 2.21 | |
ROIC | -0.16 | -0.17 | -0.18 | -0.24 | -0.28 | |
Return on tangible assets | -0.13 | -0.15 | -0.16 | -0.16 | -0.24 | |
Graham Net | 2.26 | 1.28 | 0.7 | 0.64 | 0 | |
Working capital | 185.68M | 177.69M | 169.01M | 164.49M | 124.62M | |
Tangible asset value | 116M | 85.09M | 57.34M | 54.54M | 16.77M | |
Net current asset value | 97.03M | 57.47M | 50.75M | 48.77M | 11.1M | |
Invested capital | 0.63 | 1.23 | 1.84 | 1.36 | 6.54 | |
Average receivables | 4.87M | 9.02M | 8.46M | 4.76M | 4.04M | |
Average payables | 4.59M | 5.4M | 3.38M | 2.46M | 3.31M | |
Average inventory | 90.5K | 57K | 1.36M | 2.71M | 2.57M | |
Days sales outstanding | 79.77 | 101.38 | 77.46 | 52.51 | 47.55 | |
Days payables outstanding | 1.95K | 1.95K | 536.74 | 519.43 | 356 | |
Days of inventory on hand | 23.73 | 16.17 | 623.47 | 541.19 | 214.59 | |
Receivables turnover | 1.13 | 0.89 | 1.16 | 1.71 | 1.89 | |
Payables turnover | 0.05 | 0.05 | 0.17 | 0.17 | 0.25 | |
Inventory turnover | 3.79 | 5.57 | 0.14 | 0.17 | 0.42 | |
ROE | -0.3 | -0.41 | -0.56 | -0.6 | -2.49 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
MRNS Frequently Asked Questions
What is Marinus Pharmaceuticals, Inc. stock symbol ?
Marinus Pharmaceuticals, Inc. is a US stock , located in Radnor of Pa and trading under the symbol MRNS
What is Marinus Pharmaceuticals, Inc. stock quote today ?
Marinus Pharmaceuticals, Inc. stock price is $1.44 today.
Is Marinus Pharmaceuticals, Inc. stock public?
Yes, Marinus Pharmaceuticals, Inc. is a publicly traded company.